About Us

Our Team

Leadership

Ronald Andrews

President and CEO

Ronnie Andrews joined Oncocyte as Chief Executive Officer in July 2019. Before joining Oncocyte, Ronnie was the founder and principal of the Bethesda Group LLC; a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace.

Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent.

Before this, Ronnie held several other high-profile executive roles, including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ, which was sold to General Electric Healthcare in December 2010.

Ronnie is a passionate ambassador for the need for democratization of information into community-based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He regularly speaks to industry groups and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.

Mitch Levine

Chief Financial Officer

Mitch Levine joined Oncocyte as Chief Financial Officer in November 2017. Before joining Oncocyte, Mr. Levine was the Managing Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding collaboration and investment in US-based life sciences companies.

In 2002, Mr. Levine founded Enable Capital Management and grew the firm into one of the largest and most respected brands globally in alternative finance. Its flagship fund, Enable Growth Partners, provided growth capital to more than 500 private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy.

Before founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies.

He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.

Al Parker

Chief Operating Officer

Al Parker joined Oncocyte as Chief Operating Officer in August 2018. Mr. Parker is an accomplished business and legal executive with over 25 years of broad domestic and international life sciences experience, having served in executive leadership roles in leading pharmaceutical, biotech, and healthcare companies.

With a background in strategic planning, business development, and operations, Mr. Parker’s prior roles include Executive Vice President, General Counsel and Corporate Secretary for Sunovion Pharmaceuticals, Senior Vice President and Global Chief Counsel for Wyeth Pharmaceuticals, and Managing Shareholder at GC Legal Advisors, where he also served in interim chief legal and compliance officer and other operating roles at several early-stage biotechs, pharma, and other healthcare-related companies.

Committed to strong corporate governance, Mr. Parker has been recognized as a Board Governance Fellow by the National Association of Corporate Directors. Mr. Parker earned his Juris Doctor from the University of Pennsylvania Law School and his undergraduate degree in Economics from Penn State University.

Lyndal Hesterberg Ph.D.

Chief Scientific Officer

Lyndal Hesterberg, Ph.D., joined Oncocyte as a consultant in 2015 and was named Vice President of Development in February of 2016.

Dr. Hesterberg has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial design, product development, and corporate strategy. Previously, he was the CTO at Crescendo Biosciences until 2012, where he was responsible for the clinical trial, laboratory operations, manufacturing, and quality systems and helped bring to market Vectra DA.

Before that, he was the president and CEO of Barofold, Inc., where he led the Company from product conception through its clinical stage. He also recruited a senior leadership team that developed a pipeline of proprietary drug candidates.

Dr. Hesterberg also has been a Director of Research, EVP of Scientific affairs, and Manager of Diagnostic Product Development. He received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.

Padma Sundar

Senior Vice President, Commercial

Padma Sundar has extensive experience in launching oncology tests for global diagnostics companies, helping them achieve market leadership positions.

Before joining Oncocyte, Ms. Sundar served as Vice President of Strategy and Market Access at CellMax Life, where she launched the first blood test for preventative colon cancer screening. Before CellMax, she was a Director of Marketing at Guardant Health, where she drove a 75% increase in test volume and adoption by U.S. oncologists.

As a Senior Director at Roche Sequencing, she launched the first next-generation sequencing (NGS) liquid biopsy kit for cancer recurrence monitoring. She was also Senior Director for the oncology portfolio at Affymetrix, where she brought the first whole-genome microarray kits “OncoScan” and “CytoScan” for solid and liquid tumor profiling to 50 leading academic and reference labs worldwide.

Ms. Sundar began her career at McKinsey and Company. She received her M.B.A. and M.P.H. from the University of California, Berkeley, and her B.A. in Chemistry from the University of Delhi.

Dr. Kim Dickinson

Vice President, Clinical Operations

Dr. Dickinson has over two decades of industry expertise in overseeing global clinical trials and diagnostic testing, with an emphasis on anatomic, clinical, and digital pathology.

Before joining Oncocyte, Dr. Dickinson served as Vice President of R&D and Chief Pathologist at BioCare Medical, where she led a team responsible for the R&D and testing of antibody optimizations to support the launch and release of a new immunohistochemistry instrument. Before BioCare, she was a Vice President of Clinical Operations at Roche Tissue Diagnostics, where she provided strategic, operational leadership supporting the coordination and execution of more than 100 companion diagnostic, in vitro diagnostic clinical trials.

Previously, at Laboratory Corporation of America, she was the Medical Director for the Clinical Trials Division, where she directed daily operations across five global anatomic pathology lab testing sites, as well as Medical Director for Esoteric Testing, where she led a team of pathologists and operations staff.

She received her M.D. from Hahnemann University, her M.B.A. and M.P.H. from the University of California, Irvine, and her B.Sc. in Pharmacy from the University of Pittsburgh.

Meet Our Scientific & Medical

Advisors

David R. Gandara

MD

David R. Gandara, MD, Professor of Medicine Emeritus at the University of California at Davis (UC Davis) School of Medicine, is the Senior Advisor to the Director, and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). He is an internationally known clinician-scientist, and lung cancer thought leader. He has led many notable research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trials through the Southwest Oncology Group (SWOG), and multi-institutional translational science projects. He has been selected for many awards and honors, including the Lifetime Scientific Award from the International Association for the Study of Lung Cancer (IASLC) Dr. Gandara is the principal investigator for a National Cancer Institute (NCI) UG1 award to UCDCCC for Cancer Clinical Trials. He also is currently the principal investigator for UCDCCC for the Stand Up To Cancer (SU2C) dream team award in KRAS-mutated lung cancer and served as Clinical Director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer. He is past chair of the Southwest Oncology Group (SWOG) Lung Committee and is a founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts, and editorials. He is past editor-in-chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and served as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He consults for several pharmaceutical and cancer biomarker development companies.

Thomas Bauer

MD

Dr. Bauer graduated from Jefferson Medical College and pursued his training in general surgery, research, and cardiothoracic surgery at Thomas Jefferson University Hospital. He served as the Chief of Thoracic Surgery at the Helen F Graham Cancer Center at Christiana Care Health System. Dr. Bauer currently serves as the Chief of Thoracic Surgery at Jersey Shore University Hospital. He is the Medical Director of Thoracic Oncology at Meridian Health in the Hackensack Meridian Health System. Dr. Bauer has led numerous clinical trials and has partnered with industry through device and pharmaceutical investigative trials for many years. He has authored over 100 manuscripts, chapters, abstracts, and presentations related to thoracic surgery. He has a particular interest in lung cancer screening research and clinical trials. His clinical expertise is in robotic minimally invasive thoracic surgery for the treatment of lung cancer, first rib resections, esophageal cancer, benign foregut surgery, and diaphragmatic pacing and reconstruction.

D. Kyle Hogarth

MD, FCCP

Dr. Hogarth is an Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at The University of Chicago. He is the Director of Bronchoscopy and is heavily involved in the field of interventional bronchoscopy with numerous publications. Dr. Hogarth received his medical degree at Case Western Reserve University School of Medicine in Cleveland, Ohio. He then completed a residency in Internal Medicine and a fellowship in Pulmonary and Critical Care at The University of Chicago. He is published in the New England Journal of Medicine, Chest, along with many other journals. He serves on the editorial board of CHEST, where he is the section editor for the podcast section.

Edward F. Patz Jr.

MD

Dr. Patz is the James and Alice Chen Professor of Radiology and a Professor in Pharmacology and Cancer Biology at Duke University Medical Center. He began his training in High Energy Physics at Harvard University, received his MD from the University of Maryland, completed his residency and thoracic imaging fellowship at the Brigham and Women’s Hospital and Harvard Medical School, and then was appointed to the faculty in the Department of Radiology at the Brigham, Harvard Medical School, and the Dana Farber Cancer Institute. In 1991, he was recruited to the Thoracic Imaging section in the Department of Radiology at Duke. Dr. Patz is a clinician-scientist, with projects that focus on early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. He has participated in numerous clinical trials, including the National Lung Screening Trial (NLST), and for over 20 years has been the principal investigator of a basic science laboratory exploring lung cancer biology.

Contact Us